Nephritis, clinical trials and biomarkers rank highest among research priorities related to childhood-onset systematic lupus erythematosus, according to a survey of rheumatologists, dermatologists ...

Access free, up-to-date clinical references on the pathogenesis and pathophysiology of Lupus at Healio. We aid in making confident point-of-care decisions.

Overview of SLE and LN, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines. Annualized SLE and LN therapeutics market revenue, annual cost of therapy ...

PRESS RELEASE GlobeNewswire Jun. 16, 2020, 08:44 AM Dublin, June 16, 2020 (GLOBE NEWSWIRE) -- The "Systemic Lupus Erythematosus and Lupus Nephritis: Global Drug Forecast and Market Analysis to ...

Synopsis Despite its flawed safety and efficacy, cyclophosphamide remains the standard therapy for severe lupus nephritis. Mycophenolate mofetil shows promise as an alternative. To determine ...

Results from a small, independently funded, double-blind, active-comparator trial suggest that baricitinib could be beneficial in the treatment of lupus nephritis.

How do you monitor patients with lupus nephritis for disease progression and treatment response? (Dr. Larranaga) Three-year follow-up results of voclosporin from the AURORA-2 study were published ...

A novel technology for home monitoring of lupus nephritis that tracks the pathogenic urine biomarker ALCAM. Frontiers in Immunology, 2022; 13 DOI: 10.3389/fimmu.2022.1044743 ...

In a phase 3, randomized, controlled trial, we assigned adults with biopsy-proven active lupus nephritis in a 1:1 ratio to receive obinutuzumab in one of two dose schedules (1000 mg on day 1 and ...

Lupus nephritis occurs when the immune system attacks the kidneys, leading to inflammation and potential organ damage. It affects 30-50% of pediatric lupus patients, typically within the first two ...